The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a
life expectancy comparable to that of the general population thanks to the use of tyrosine …

Since the introduction of imatinib, the management of chronic myeloid leukemia (CML) has
changed considerably. Tyrosine kinase inhibitors (TKIs) are the mainstay of CML treatment; …

Introduction Imatinib is standard therapy for patients with chronic myeloid leukemia (CML). In
February 2016, a generic formulation entered the US market. Physicians and patients are …

In order to harmonize and standardize the management of patients with chronic myeloid
leukemia (CML), the European LeukemiaNet (ELN) produced recommendations in the …

Tyrosine kinases inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment
for many years, prolonging patients' life expectancy to be comparable to age-matched …

Introduction Since the introduction of first tyrosine kinase inhibitor (TKI) imatinib, the
treatment of chronic myeloid leukemia (CML) has reached excellent survival expectancies …

In India, CML is the commonest adult leukemia. Imatinib is the gold standard for frontline
treatment of newly diagnosed CML-CP patients. The present study was conducted to assess …

The use of generic drugs after patent expiration of their originators is a relative novelty in the
treatment of chronic cancer patients in Western countries. In this observational study we …